JP2009519313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519313A5 JP2009519313A5 JP2008545097A JP2008545097A JP2009519313A5 JP 2009519313 A5 JP2009519313 A5 JP 2009519313A5 JP 2008545097 A JP2008545097 A JP 2008545097A JP 2008545097 A JP2008545097 A JP 2008545097A JP 2009519313 A5 JP2009519313 A5 JP 2009519313A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- drug
- stearic acid
- composition
- ethylcellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 9
- 239000001856 Ethyl cellulose Substances 0.000 claims 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 7
- 235000021355 Stearic acid Nutrition 0.000 claims 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims 7
- 229920001249 ethyl cellulose Polymers 0.000 claims 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 7
- 239000008117 stearic acid Substances 0.000 claims 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229920002472 Starch Polymers 0.000 claims 5
- 239000008107 starch Substances 0.000 claims 5
- 235000019698 starch Nutrition 0.000 claims 5
- 239000000454 talc Substances 0.000 claims 5
- 229910052623 talc Inorganic materials 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 229940035722 triiodothyronine Drugs 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- -1 ethoxyl Chemical group 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 230000002989 hypothyroidism Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 238000001125 extrusion Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 238000005563 spheronization Methods 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
- 239000005495 thyroid hormone Substances 0.000 claims 1
- 229940036555 thyroid hormone Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0525461.0A GB0525461D0 (en) | 2005-12-15 | 2005-12-15 | Pharmaceutical compositions |
| PCT/GB2006/004710 WO2007068948A2 (en) | 2005-12-15 | 2006-12-15 | Pharmaceutical sustained release compositions comprising in particular thyroid hormones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519313A JP2009519313A (ja) | 2009-05-14 |
| JP2009519313A5 true JP2009519313A5 (enExample) | 2009-12-24 |
Family
ID=35736122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545097A Pending JP2009519313A (ja) | 2005-12-15 | 2006-12-15 | 医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8460702B2 (enExample) |
| EP (1) | EP1978950A2 (enExample) |
| JP (1) | JP2009519313A (enExample) |
| BR (1) | BRPI0619934A2 (enExample) |
| CA (1) | CA2634006C (enExample) |
| GB (1) | GB0525461D0 (enExample) |
| IL (1) | IL192091A (enExample) |
| WO (1) | WO2007068948A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057464A2 (en) * | 2006-11-01 | 2008-05-15 | King Pharmaceuticals Research And Development, Inc. | Compositions and methods for improving the bioavailability of liothyronine |
| US9526701B2 (en) | 2011-12-20 | 2016-12-27 | Keith R. Latham | Sustained drug release and improved product stability using non-covalent particle coating methods |
| WO2015153984A2 (en) * | 2014-04-04 | 2015-10-08 | Pharmaquest International Center, LLC | Disintegrating monolithic modified release tablets containing quadri-layer extended release granules |
| ES2630106T3 (es) * | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
| US10695309B2 (en) | 2017-03-31 | 2020-06-30 | Western New England University | Sustained-release liothyronine formulations, method of preparation and method of use thereof |
| PE20211489A1 (es) | 2018-08-31 | 2021-08-11 | Opko Ireland Global Holdings Ltd | Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso |
| US20220409567A1 (en) * | 2021-06-23 | 2022-12-29 | Thomas Winston | Adjuvant and complementary therapies for the treatment of cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806359A (en) | 1987-04-22 | 1989-02-21 | Mcneilab, Inc. | Iburprofen sustained release matrix and process |
| US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| EP0550108B1 (en) | 1991-12-30 | 1998-03-18 | Akzo Nobel N.V. | Sustained release thyroactive composition |
| GB9401892D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| AU2117399A (en) | 1998-01-20 | 1999-08-02 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| DE19821625C1 (de) * | 1998-05-15 | 2000-01-05 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| WO1999063969A1 (en) * | 1998-06-08 | 1999-12-16 | Groenewoud Pieter J | Stabilized thyroxine medications |
| IL141762A0 (en) | 1998-10-01 | 2002-03-10 | Novartis Ag | New oral formulations |
| US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| US6288117B1 (en) | 2000-03-23 | 2001-09-11 | North Shore-Long Island Jewish Research Institute | Method for treating congestive heart failure |
| CZ20023003A3 (cs) | 2000-03-30 | 2002-11-13 | Bristol-Myers Squibb Company | Perličky s trvalým uvolňováním obsahující stavudin |
| AU2001253287B2 (en) * | 2000-04-10 | 2005-04-28 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| AU2003231919A1 (en) * | 2002-03-14 | 2003-09-22 | Sun Pharmaceutical Industries Limited | Oral controlled drug delivery system containing carbamazepine |
| ITMI20022394A1 (it) * | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| AU2006230557A1 (en) * | 2005-03-31 | 2006-10-05 | King Pharmaceuticals Research & Development, Inc. | Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same |
-
2005
- 2005-12-15 GB GBGB0525461.0A patent/GB0525461D0/en not_active Ceased
-
2006
- 2006-12-15 US US12/097,163 patent/US8460702B2/en not_active Expired - Fee Related
- 2006-12-15 CA CA2634006A patent/CA2634006C/en not_active Expired - Fee Related
- 2006-12-15 EP EP06820546A patent/EP1978950A2/en not_active Withdrawn
- 2006-12-15 BR BRPI0619934-8A patent/BRPI0619934A2/pt not_active IP Right Cessation
- 2006-12-15 JP JP2008545097A patent/JP2009519313A/ja active Pending
- 2006-12-15 WO PCT/GB2006/004710 patent/WO2007068948A2/en not_active Ceased
-
2008
- 2008-06-12 IL IL192091A patent/IL192091A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0715853A2 (pt) | uso de poliàis para obter formas polimorfas estÁveis de rifaximina | |
| JP2014167026A5 (enExample) | ||
| JP2016525572A5 (enExample) | ||
| JP2009537478A5 (enExample) | ||
| JP2010083886A5 (enExample) | ||
| EP3318283B1 (en) | Hypromellose acetate succinate and method for producing the same | |
| JP2025085845A (ja) | ブルトン型チロシンキナーゼ阻害剤を含む経口固体錠剤及びその調製方法 | |
| JP2014237658A5 (enExample) | ||
| JPWO2013054872A1 (ja) | ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤 | |
| CZ20004201A3 (cs) | Farmaceutický prostředek obsahující Levothyroxin natrium a způsob jeho výroby | |
| TW200900096A (en) | Tablet coatings made from modified carboxymethylcellulose materials | |
| US20120093939A1 (en) | Oral formulations | |
| JP2009519313A5 (enExample) | ||
| RU2008136767A (ru) | Фармацевтическая композиция флувастатина натрия | |
| CN101862305B (zh) | 一种盐酸氨溴索缓释微丸及制备方法 | |
| ITFI20100175A1 (it) | Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system). | |
| JP2014169318A5 (enExample) | ||
| CN101912374A (zh) | 喹硫平缓释片及其制备方法 | |
| CN101700248A (zh) | 一种阿司卡托肠溶缓释胶囊的制备方法 | |
| CN103919744B (zh) | 一种头孢特仑新戊酯片及其制备工艺 | |
| JP5461084B2 (ja) | 崩壊遅延が抑制されたパロキセチン塩酸塩水和物の経口投与用医薬組成物 | |
| JP2009544684A5 (enExample) | ||
| JP2009057331A (ja) | グリメピリド含有製剤 | |
| JP2009519313A (ja) | 医薬組成物 | |
| CN110314150A (zh) | 一种替米沙坦风味咀嚼片及其制备方法 |